Quick Take: MRK‘s Enlicitide (now LIPFENDRA) approved by CNPV undercutting other PCSK9s

Research evidence excerpt

Quick Take: MRK‘s Enlicitide (now LIPFENDRA) approved by CNPV undercutting other PCSK9s

ned regulators and does not represent any official recommendation from the aforementioned

regulators. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in

consultation with advice sought from a financial adviser regarding the suitability of the investment product, taking into account the

specific investment objectives, financial situation or particular needs of any recipient of the recommendation, before the recipient

makes a commitment to purchase the investment product.

The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different

results. The information in this report does not constitute, or form part of, any offer to sell or issue, or any offer to purchase or

subscribe for shares, or to induce engagement in any other investment activity. The value of any securities or financial instruments

mentioned in this report may fluctuate subject to market conditions. Information about past performance of an investment is

not necessarily a guide to, indicative of, or assurance of future performance. Estimates of future performance mentioned by

the research analyst in this report are based on assumptions that may not be realized due to unforeseen factors like market

volatility/fluctuation. In relation to securities or financial instruments denominated in a foreign currency other than the clients’

home currency, movements in exchange rates will have an effect on the value, either favorable or unfavorable. Before acting on any

recommendations in this report, recipients should consider the appropriateness of investing in the subject securities or financial